NCT00305019终止2 期
A Double- Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 Mg QD and 50 Mg QD Doses in Patients Infected With Hepatitis B Virus
Bukwang Pharmaceutical16 个研究点 分布在 2 个国家目标入组 120 人开始时间: 2002年7月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 120
- 试验地点
- 16
- 主要终点
- Efficacy: Change from baseline in HBV DNA (log10)
研究概览
简要总结
The purpose of this study is to determine the antiviral effects and safety of clevudine 30 mg once a day (QD) and 50 mg QD in patients infected with hepatitis B virus (HBV).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient who is between 18 and 60 years of age, inclusive
- •Patient who is HBV DNA positive with DNA levels at screening more than 3 x 10^6 copies/mL.
- •Patient who is documented to be hepatitis B surface antigen (HBsAg) positive for > 6 months. Patient is HBeAg positive and anti-HBe negative.
- •Evidence of HBsAg (+) for the previous 6 months may include the following:
- •documentation of HBsAg (+) for the previous 6 months
- •documentation of HBsAg (+) for the previous 3 months and IgM anti-HBc negative at screening
- •IgM anti-HBc negative and IgG anti-HBc positive at screening
- •Patient who has ALT levels which are in the range of more than 2 to less than 10 times the upper limit of normal (x ULN) and bilirubin levels < 1.5 x ULN.
- •Female patient with a negative serum (HCG) pregnancy test taken within 14 days of starting therapy.
- •Patient who is able to give written informed consent prior to study start and to comply with the study requirements.
- •Patients who continue to meet the following criteria after completion of the Week 36 visit will have additional follow-up visits at Week 40, 44, 48:
- •have received no additional therapy since completion of 12 weeks of treatment of L-FMAU and
- •continue with period 1 log10 decrease in HBV DNA from baseline.
排除标准
- •Patient who is currently receiving antiviral, immunomodulatory or corticosteroid therapy.
- •Patients previously treated with lamivudine, lobucavir, adefovir or any other investigational nucleoside for HBV infection.
- •Patients with previous treatment with interferon that have ended less than 6 months prior to the screening visit.
- •Patient who has a history of ascites, variceal hemorrhage or hepatic encephalopathy.
- •Patient who is coinfected with hepatitis C virus (HCV), hepatitis D virus (HDV) or HIV.
- •Patient with clinical evidence of cirrhosis or hepatocellular carcinoma
- •Patient who is pregnant or breast-feeding.
- •Patient who is unwilling to use an "effective" method of contraception during the study and for up to 30 days after the use of study drug ceases. For males, condoms should be used. Females must be surgically sterile (via hysterectomy or bilateral tubal ligation), post-menopausal or using at least a medically acceptable barrier method of contraception (i.e., intrauterine device [IUD], barrier methods with spermicide or abstinence)
- •Patient who has a clinically relevant history of abuse of alcohol or drugs.
- •Patient who has a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease.
- •Patient who has creatinine clearance less than 60 mL/min as estimated by the following formula:
- •(140-age in years) (body weight [kg])/ (72) (serum creatinine [mg/dL]) [Note: multiply estimates by 0.85 for women]
- •Patients found to have tyrosine, methionine, aspartate, aspartate (YMDD) HBV DNA polymerase mutation after the enrollment will be excluded from the efficacy evaluation but included in the safety evaluation.
结局指标
主要结局
Efficacy: Change from baseline in HBV DNA (log10)
次要结局
- Efficacy: Proportion of patients with HBV DNA below 1 pg/mL
- Proportion of patients with HBV DNA below the assay limit of detection (LOD) (SuperDigene HC test II LOD, <4,700 copies/mL)
- Proportion of patients with hepatitis Be antigen (HBeAg) loss
- Seroconversion rate (HBeAg loss and hepatitis Be antibody [HBeAb] positivity)
- Biochemical improvement (e.g., ALT normalization)
- Safety
- Laboratory tests
- Adverse Events
- Vital Signs
- Electrocardiogram (ECG)
研究者
研究点 (16)
Loading locations...
相似试验
终止
3 期
Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBVHepatitis BNCT00313287Bukwang Pharmaceutical180
已完成
2 期
The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19COVID-19NCT04347915Bukwang Pharmaceutical64
已完成
2 期
The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19COVID-19NCT04891302Bukwang Pharmaceutical104
终止
2 期
Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo GroupHepatitis BNCT00313261Bukwang Pharmaceutical
终止
3 期
Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBVHepatitis BNCT00313274Bukwang Pharmaceutical80